SEARCH

SEARCH BY CITATION

References

  • Breccia, M., Salaroli, A., Loglisci, G., Finsinger, P., Serrao, A. & Alimena, G. (2012) MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine. Haematologica, 97, e2.
  • Dayyani, F., Conley, A.P., Strom, S.S., Stevenson, W., Cortes, J.E., Borthakur, G., Faderl, S., O'Brien, S., Pierce, S., Kantarjian, H. & Garcia-Manero, G. (2010) Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer, 116, 21742179.
  • Della Porta, M.G., Malcovati, L., Strupp, C., Ambaglio, I., Kuendgen, A., Zipperer, E., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., Germing, U. & Cazzola, M. (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica, 96, 441449.
  • Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, 10, 223232.
  • Follo, M.Y., Finelli, C., Mongiorgi, S., Clissa, C., Bosi, C., Testoni, N., Chiarini, F., Ramazzotti, G., Baccarani, M., Martelli, A.M., Manzoli, L., Martinelli, G. & Cocco, L. (2009) Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to Azacitidine in high-risk MDS. Proceedings of the National Academy of Sciences U S A, 106, 1681116816.
  • Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Turlure, P., Vey, N., Recher, C., Dartigeas, C., Legros, L., Delaunay, J., Salanoubat, C., Visanica, S., Stamatoullas, A., Isnard, F., Marfaing-Koka, A., de Botton, S., Chelghoum, Y., Taksin, A.L., Plantier, I., Ame, S., Boehrer, S., Gardin, C., Beach, C.L., Adès, L. & Fenaux, P. (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood, 117, 403411.
  • Naqvi, K., Garcia-Manero, G., Sardesai, S., Oh, J., Vigil, C.E., Pierce, S., Lei, X., Shan, J., Kantarjian, H.M. & Suarez-Almazor, M.E. (2011) Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. Journal of Clinical Oncology, 29, 22402246.
  • Ozbalak, M., Cetiner, M., Bekoz, H., Atesoglu, E.B., Ar, C., Salihoglu, A., Tuzuner, N. & Ferhanoglu, B. (2012) Azacitidine has limited activity in ‘real life’ patients with MDS and AML: a single centre experience. Hematology Oncology, 30, 7681.
  • Piccirillo, J.F., Costas, I., Claybour, P., Borah, A.J., Grove, L. & Jeffe, D. (2003) The measurement of comorbidity by cancer registries. Journal of Registry Management, 30, 814.